Macular vessel density in the superficial plexus is not a proxy of cerebrovascular damage in non-demented individuals: data from the NORFACE cohort

Table 2 Biomarker data of the study cohort

Variables	Whole cohort (n = 188)	SCD (n = 89)	MCI (n = 99)	Significance
A + status	53 (28.19%)	28 (31.46%)	25 (25.25%)	0.434 ^b
Brain MRI
Fazekas category 2–3	20 (10.64%)	13 (14.61%)	7 (7.07%)	0.151 ^b
WMH volume (mm³)	3203.91 ± 4506.54	3408.14 ± 4752.04	3020.31 ± 4289.90	0.559 ^a
OCT-A
VD nasal	47.66 ± 3.81	47.03 ± 3.16	48.23 ± 4.24	0.028* ^a
VD superior	48.67 ± 4.74	48.11 ± 4.18	49.17 ± 5.16	0.124 ^a
VD temporal	45.83 ± 3.42	44.97 ± 2.94	46.59 ± 3.65	0.001* ^a
VD inferior	47.81 ± 5.44	46.89 ± 4.40	48.65 ± 6.14	0.024* ^a

Data are shown as mean ± standard deviation for quantitative variables and n (%) for qualitative variables
A + status was defined as FBB-PET Centiloid > 13.5 in the FACEHBI study and CSF Aβ42/Aβ40 ratio < 0.063 in the BIOFACE study
Abbreviations: A Amyloid, MCI Mild cognitive impairment, MRI Magnetic resonance imaging, OCT-A Optical coherence tomography – angiography, SCD Subjective cognitive decline, VD Vessel density, WMH White matter hyperintensity
^*Significance was set up at p < 0.05
^aStudent’s t test; ^bPearson’s chi-square test

ISSN: 1758-9193